Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders

Digestive Diseases and Sciences

Volumn 57, Issue 11, 2012, Pages 3011-3016

  Yip, Benjamin ^a   Chaung, Kevin ^b   Wong, Carrie R ^b   Trinh, Huy N ^b,c   Nguyen, Huy A ^b,c   Ahmed, Aijaz ^a   Cheung, Ramsey ^d   Nguyen, Mindie H ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Pacific Health Foundation   (United States)

^c San Jose Gastroenterology   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Combination therapy; Nonresponse; Suboptimal; Switch; Virologic response

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CLINICAL ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; VIRUS RESISTANCE;

ADENINE; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84871620642     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2402-2     Document Type: Article

References (24)

1. Lavanchy D, Hepatitis B. virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
2. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
4. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26:162-170.
5. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-1341; quiz 286.
6. Chang TT, Chao YC, Gorbakov VV, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2009;16:784-789.
7. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020.
8. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology. 2009;49:72-79.
9. Leung N, Peng CY, Sollano J, et al. Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviralna? ̈ve HBeAg(+) adults with high HBVDNA: week 96 results (EARLY study). J Hepatol. 2008;48:S373-S374.
10. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaïve patients is rare through 5 years of therapy. Hepatology. 2009;49:1503-1514.
11. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276-1282.
12. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:614-622.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131: 1743-1751.
14. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750-758.
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539.
16. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2010;52:493-500.
17. Nguyen M, Trinh H, Do S, et al. Response to entecavir (ETV) in patients with chronic hepatitis B (CHB) and prior suboptimal response to adefovir (ADV): interim report of a multicenter study. Gastroenterology. 2009;136:A798.
18. Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 2012;19:213-219.
19. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854-1863.
20. Ha NB, Garcia RT, Trinh HN, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigennegative chronic hepatitis B. Dig Dis Sci. 2011;56:2423-2431.
21. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430.
22. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443-451.
23. Lok AS, Trinh H, Carosi G, et al. Efficacyof entecavir with orwithout tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 2012;143:619-628.
24. Wong CR, Trinh HN, Yip B, et al. High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. J Clin Gastroenterol. 2011;45:900-905.